Michael McMahon
Medical · Wallingford, CTNPI 1629072442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Abbott at 30.2% of the total. Reporting peaked in 2024 at $1,903 and has fallen 61.5% since, to $732 in 2025. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $33.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boehringer Ingelheim$425
- Impulse Dynamics (USA) Inc.$384
- Johnson & Johnson$368
- Novartis$350
- E.r. Squibb & Sons, L.L.C.$314
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1883%
- Food & beverage$5,93297%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $1,849 |
| Boehringer Ingelheim | 15 | $425 |
| Impulse Dynamics (USA) Inc. | 5 | $384 |
| Johnson & Johnson | 10 | $368 |
| Novartis | 15 | $350 |
| E.r. Squibb & Sons, L.L.C. | 14 | $314 |
| AstraZeneca | 11 | $312 |
| Merck | 14 | $301 |
| Heartflow, Inc. | 7 | $296 |
| Novo Nordisk | 12 | $284 |
| Medtronic | 5 | $255 |
| Pfizer | 11 | $244 |
| GE HealthCare | 1 | $188 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $107 |
| Boston Scientific | 4 | $99 |
| Alnylam Pharmaceuticals Inc. | 2 | $58 |
| Scpharmaceuticals Inc. | 3 | $53 |
| Bayer | 2 | $49 |
| Atricure, Inc. | 1 | $36 |
| Baxter Healthcare | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Amgen | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Bracco Diagnostics Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,120 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $262,787 |
| EntrestoSacubitril/Valsartan | 78 | $119,539 |
| Repatha SureclickEvolocumab | 98 | $105,705 |
| FarxigaDapagliflozin Propanediol | 73 | $74,973 |
| XareltoRivaroxaban | 29 | $43,546 |
| JardianceEmpagliflozin | 30 | $34,252 |
| OzempicSemaglutide | 18 | $17,970 |
| Praluent PenAlirocumab | 15 | $14,890 |
| BrilintaTicagrelor | 18 | $11,515 |
| Metoprolol Succinate | 373 | $4,686 |
| VascepaIcosapent Ethyl | 16 | $4,654 |
| Rosuvastatin Calcium | 289 | $4,236 |
| Ranolazine ErRanolazine | 15 | $3,075 |
| Atorvastatin Calcium | 206 | $2,007 |
| Valsartan | 91 | $1,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $244 | $262,787187 claims |
| NovartisEntresto | $350 | $119,53978 claims |
| AstraZenecaFarxiga, Brilinta | $312 | $86,48891 claims |
| Johnson & JohnsonXarelto | $368 | $43,54629 claims |
| Boehringer IngelheimJardiance | $425 | $34,25230 claims |
| Novo NordiskOzempic | $284 | $17,97018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 592 medical providers in Connecticut.
Other medical in Wallingford
- Anton CherryWallingford$5K
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.